A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.
NCT04494984
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
243
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Interventions
DRUG:
INM005
DRUG:
Placebo
Sponsor
Inmunova S.A.